Avenue Therapeutics Inc Quick Ratio (ATXI) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Avenue Therapeutics Inc   (ATXI)

Avenue Therapeutics Inc 's Quick Ratio

ATXI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.95 below Avenue Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Avenue Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 799 to 1705.

Explain Quick Ratio?
How much Cash & cash equivalents ATXI´s has?
What are ATXI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATXI Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 12.87 % 5.87 % 0.63 % 34.68 % 46.15 %
Y / Y Cash & cash equivalent Change -59.02 % -41.61 % -30.98 % 10.06 % 42.82 %
Quick Ratio MRQ 0.95 1.38 1.9 2.6 2.61
ATXI's Total Ranking # 1705 # 799 # 953 # 865 #
Seq. Current Liabilities Change 14.07 % 10.79 % 15.56 % -22.71 % 7 %
Seq. Cash & cash equivalent Change -21.73 % -19.65 % -15.34 % -23.03 % 11.52 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 327
Healthcare Sector # 579
Overall Market # 1705


Quick Ratio Statistics
High Average Low
104.66 6.08 0.03
(Jun 30 2024)   (Sep 30 2023)




Financial Statements
Avenue Therapeutics Inc 's Current Liabilities $ 2 Millions Visit ATXI's Balance sheet
Avenue Therapeutics Inc 's Cash & cash equivalent $ 2 Millions Visit ATXI's Balance sheet
Source of ATXI's Sales Visit ATXI's Sales by Geography


Cumulative Avenue Therapeutics Inc 's Quick Ratio

ATXI's Quick Ratio for the trailling 12 Months

ATXI Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 11.43 % 18.68 % 65.27 % 57.39 % 33.1 %
Y / Y Cash & cash equivalent TTM Growth -33.49 % -9.12 % -9.59 % 0.66 % 5.11 %
Quick Ratio TTM 1.62 2.1 2.4 2.62 2.72
Total Ranking TTM # 3810 # 2155 # 2892 # 3010 #
Seq. Current Liabilities TTM Growth 3.52 % 1.52 % 0.16 % 5.86 % 10.25 %
Seq. Cash & cash equivalent TTM Growth -20.04 % -11.25 % -8.1 % 1.99 % 9.25 %

Quick ratio ranking by company, industry and sector >> Back to ATXI Financial Strength Comparisons >> Go to Compare ATXI Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $1.61 millions, cumulative Quick Ratio decreased to 1.62 below the Avenue Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Avenue Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2155 to 3810.

Explain Quick Ratio?
How much Cash & cash equivalents ATXI´s has?
What are ATXI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 881
Within the Market # 3810


trailing twelve months Quick Ratio Statistics
High Average Low
5.13 2.73 0.43
(Mar 31 2020)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions
Amarin Corp Plcuk  1.85 $ 323.379  Millions$ 175.136  Millions
Biovie Inc   1.78 $ 7.733  Millions$ 4.350  Millions
Alnylam Pharmaceuticals Inc   1.74 $ 3,587.255  Millions$ 2,063.006  Millions
Insmed Inc  1.73 $ 1,146.626  Millions$ 662.181  Millions
Nkarta Inc   1.72 $ 48.354  Millions$ 28.072  Millions
Agios Pharmaceuticals Inc   1.66 $ 128.549  Millions$ 77.588  Millions
Bridgebio Pharma Inc   1.57 $ 1,538.855  Millions$ 977.237  Millions
Arcutis Biotherapeutics Inc   1.51 $ 259.460  Millions$ 172.357  Millions
Regeneron Pharmaceuticals Inc   1.50 $ 9,301.100  Millions$ 6,202.100  Millions
Emergent Biosolutions Inc   1.44 $ 175.700  Millions$ 122.000  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions
Vertex Pharmaceuticals Inc  1.26 $ 6,303.300  Millions$ 5,000.300  Millions
Nature s Sunshine Products inc   1.22 $ 89.377  Millions$ 73.488  Millions
Filana Therapeutics Inc   1.12 $ 46.990  Millions$ 41.946  Millions

Date modified: 2026-11-07T06:52:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.